Efficacy and Safety of Combined PD-1 Inhibitor With Induction Chemotherapy Followed by IMRT Plus Nimotuzumab in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Analysis

被引：0
作者：
Chen, Kebin [1 ]
Huang, Xiaopeng [2 ]
Chen, Jiawei [2 ]
Zhang, Shuai [2 ]
机构：
[1] Hainan Med Univ, Hainan Affiliated Hosp, Dept Radiat Oncol, Haikou 570311, Peoples R China
[2] Hainan Med Univ, Hainan Gen Hosp, Hainan Affiliated Hosp, Dept Radiat Oncol, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China
来源：
ONCOTARGETS AND THERAPY | 2025年 / 18卷
关键词：
nasopharyngeal carcinoma; PD-1; inhibitors; induction chemoth4erapy; IMRT; efficacy; INTENSITY-MODULATED RADIOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; CANCER; METASTASIS; OUTCOMES; HEAD; ERA;
D O I：
10.2147/OTT.S503674
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Background: Induction chemotherapy (IC) is the standard treatment protocol for locally advanced nasopharyngeal carcinoma (LANPC), though concerns persist regarding high rates of recurrence and metastasis. This retrospective study aims to evaluate the efficacy, potential benefits, and safety of combining PD-1 inhibitors with IC, followed by nimotuzumab and intensity-modulated radiation therapy (IMRT). Methodology: We analyzed data from 103 patients diagnosed with non-keratinizing LANPC (according to WHO criteria) at clinical stages III-IVA. These patients, treated from May 2020 to November 2023, received four cycles of IC combined with PD-1 inhibitors, followed by nimotuzumab and IMRT. Efficacy assessments were conducted according to RECIST v1.1 guidelines, with the primary endpoint being a clinical complete response (CCR), defined as the absence of detectable tumors or mucosal bulges upon nasoendoscopy. Results: Among the evaluable patients, the CCR rate reached 66% (95% CI, 56-75%), while the objective response rate (ORR) was 97% (95% CI, 92-99%) and the disease control rate (DCR) reached 99% (95% CI, 95-100%). During the median follow-up of 16.1 months, neither the median progression-free survival (PFS) nor median overall survival (OS) was reached. Notably, patients with T4- stage disease exhibited lower CCR rates, highlighting stage-specific variations in treatment responses. The treatment regimen was well-tolerated, with no significant adverse safety events reported. Conclusion: The combination of PD-1 inhibitors with IC, followed by nimotuzumab and IMRT, shows promising efficacy and safety in the treatment of LANPC.
引用
收藏
页码：283 / 296
页数：14
相关论文
共 45 条
  • [1] Chen Y-P, Chan AT, Le Q-T, Blanchard P, Sun Y, Ma J., Nasopharyngeal carcinoma, The Lancet, 394, 10192, pp. 64-80, (2019)
  • [2] Jacques Ferlay ME, Siegel RL, Isabelle Soerjomataram M, Ahmedin Jemal D., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, (2024)
  • [3] Yang Y, Yang X, Zhang C, Et al., Research landscape of radiotherapy for nasopharyngeal carcinoma from 1959 to 2022: a bibliometric analysis, (2023)
  • [4] Lee AW, Ng WT, Chan LL, Et al., Evolution of treatment for nasopharyngeal cancer–success and setback in the intensity-modulated radiotherapy era, Radiotherapy and Oncology, 110, 3, pp. 377-384, (2014)
  • [5] Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y., Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis, Oral Oncology, 51, 11, pp. 1041-1046, (2015)
  • [6] Li A-C, Xiao -W-W, Shen G-Z, Et al., Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy, Oncotarget, 6, 27, (2015)
  • [7] Crombet T, Osorio M, Cruz T, Et al., Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients, Journal of Clinical Oncology, 22, 9, pp. 1646-1654, (2004)
  • [8] Cao S-M, Yang Q, Guo L, Et al., Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase III multicentre randomised controlled trial, European Journal of Cancer, 75, pp. 14-23, (2017)
  • [9] You R, Hua YJ, Liu YP, Et al., Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: retrospective Analysis with a Large Cohort and Long Follow-up, Theranostics, 7, 8, pp. 2314-2324, (2017)
  • [10] Yao JJ, Zhang LL, Gao TS, Et al., Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma, Cancer Biol Ther, 19, 12, pp. 1102-1107, (2018)
12345